Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes

Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes
  • New data shows that Amarin Corporation plc's AMRN Vascepa/Vazkepa (icosapent ethyl) significantly reduced ST-segment and non-ST elevation myocardial infarction (NSTEMI) and other MI subtypes in patients with cardiovascular disease or diabetes with risk factors.
  • The REDUCE-IT study data presented show STEMI was significantly reduced by 40% following treatment with icosapent ethyl (IPE) compared to placebo. 
  • IPE also significantly reduced NSTEMI by 27%. 
  • Related: Amarin Still Suspends FY22 Guidance On Generic Challenges.
  • "This analysis of REDUCE-IT clearly shows that IPE 4 g/day as an adjunct to statin therapy in high-risk patients with residual hypertriglyceridemia provides a large and significant reduction in heart attacks," said Deepak Bhatt, principal investigator of the REDUCE-IT trial. 
  • In time to first event analyses, MI was significantly reduced with IPE treatment, with a number needed to treat (NNT) of 39. 
  • There were clinically meaningful and statistically significant reductions in MI subtypes, including MI leading to cardiac arrest and resuscitated MI. 
  • IPE also significantly reduced the overall burden of total (first and subsequent) STEMI and total NSTEMI versus placebo.
  • Price Action: AMRN shares are down 0.38% at $1.29 on the last check Friday.

Posted In: BriefsBiotechNewsPenny StocksHealth CareSmall CapGeneral